The professor of neurology at the University of Cincinnati discussed why disparities persist in secondary stroke prevention and how growing awareness of social determinants of health is helping to ...

In recent news, the FDA granted Fast Track designation to remlifanserin (ACP-204; Acadia Pharmaceuticals), an investigational selective serotonin 5-HT2A receptor inverse agonist, for the treatment of ...

The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.

Xenon Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for azetukalner (XEN1101) as adjunctive treatment for focal seizures in adults with epilepsy, based on ...

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...

A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...

Foundational health behaviors reduce migraine burden, but frequent or disabling attacks commonly require preventive treatment ...

HIMALAYA was a multicenter, randomized, double-blind, placebo-controlled phase 2 trial conducted at 63 sites across 13 ...

"Unmet Needs and Mechanisms Behind Newer Agitation Therapies" takes up what still remains unmet in agitation care, and the biology behind a newer treatment option.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes] ...

Levacetylleucine (AQNEURSA) is approved for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg, in addition to its existing indication for ...

The FDA has approved UX111 (Fayuvi; Ultragenyx Pharmaceutical), an adeno-associated virus serotype 9 (AAV9) gene therapy, for the treatment of pediatric patients with Sanfilippo syndrome type A ...